Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

November 01, 1996; 47 (5) Articles

Nonmotor fluctuations in patients with Parkinson's disease

Machteld E. Hillen, Jacob I. Sage
First published November 1, 1996, DOI: https://doi.org/10.1212/WNL.47.5.1180
Machteld E. Hillen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob I. Sage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Nonmotor fluctuations in patients with Parkinson's disease
Machteld E. Hillen, Jacob I. Sage
Neurology Nov 1996, 47 (5) 1180-1183; DOI: 10.1212/WNL.47.5.1180

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
115

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

We studied the nature and frequency of nonmotor "off" phenomena in 130 consecutive patients with Parkinson's disease (PD) with motor fluctuations.Twenty-two patients (17%) experienced nonmotor fluctuations as an end-of-dose phenomenon. Previously unreported, or little appreciated, nonmotor "off" states include sensory dyspnea, nausea, facial flushing, cough, hunger, unilateral limb edema, proximal limb pain, and trigeminal neuralgia-like pain. We attempted treatment modification in 12 of 22 patients; nonmotor "off" symptoms improved in nine of these 12 patients (75%). Recognizing these phenomena will prevent unnecessary tests and treatments.

NEUROLOGY 1996;47: 1180-1183

The majority of patients with Parkinson's disease (PD) begin to experience a fluctuating response to levodopa (LD) within 5 years of initiating treatment. [1] The most common fluctuations consist of changes in motor function presumably associated with alterations in the concentration and efficacy of striatal dopamine. [2] High concentration effects usually consist of dyskinesias (peak dose chorea or dystonia, high-dopa dyskinesias). [3] Low concentration, or reduced efficacy, of striatal dopamine is associated with the reemergence of parkinsonian motor symptoms (end-of-dose wearing off), chorea (diphasic, [4] low-dopa chorea), dystonia (early morning dystonia, low-dopa dystonia), [5] and unpredictable on-off phenomena. Other relatively frequent and disabling decreased LD efficacy symptoms, however, are nonmotor in nature (autonomic, sensory, cognitive/psychiatric). [6] The clinical spectrum and frequency of these nonmotor low-dopa phenomena among patients with fluctuating PD symptoms is not known. We therefore studied the nature and occurrence of nonmotor "off" phenomena in 130 consecutive patients with fluctuating PD symptoms and describe a number of previously unrecognized, or little appreciated, nonmotor symptoms associated with the "off" state.

Methods.

During a 6-month period (March 1, 1995 through August 31, 1995), we screened 130 consecutive patients with PD and motor fluctuations during routine outpatient visits. In a nondirected fashion, we asked every patient to tell us about any symptoms they associated with the "off" state. We took an extended history of all patients who had nonmotor "off"-phenomena and correlated these symptoms with documented "off"-state signs such as tremor, rigidity, or akinesia.

Patients and results.

Twenty-two of 130 patients (17%) had 16 different symptoms of nonmotor "off"-phenomena as listed in Table 1. Nonmotor fluctuations were divided into three categories: sensory, autonomic, and cognitive/psychiatric. [6] Autonomic complaints were the most frequent, with 10 different symptoms (44% of the total complaints) seen in 15 patients. Three different cognitive/psychiatric symptoms were responsible for 11 complaints (32%). Eight sensory complaints (24%) resulted from three different symptoms. In 12 patients, either an agonist was added or the LD regimen rearranged to reduce the "off" time. Nonmotor fluctuations improved in nine of these patients (75%).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1. Number of patients with each type of nonmotor fluctuation

Patient 1 (nausea).

A 60-year-old man with PD for 5 years began having motor fluctuations 1 year ago on a schedule of controlled-release carbidopa/levodopa (CD/LD) (50/200 mg) taken at 8 AM, 1 PM, and 5 PM. He noted end-of-dose wearing off 4 hours after each dose with reemergence of tremor and bradykinesia. During the "off"-periods, the patient experienced nausea, which resolved when the next dose of LD began to take effect. Adding Cabergoline (2.5 mg) each morning resolved both the motor and nonmotor "off"-period symptoms.

Patient 2 (proximal limb burning).

A 70-year-old man with PD for 8 years has had motor fluctuations for 4 years. He takes immediate-release CD/LD (20/200 mg) every 2.5 hours from 6 AM to 9 PM with up to two additional doses at various times during the night. He also takes pergolide, 0.5 mg at 8 AM, 12 noon, and 4 PM. On this schedule, he is "on" most of the day and experiences end-of-dose wearing off during the night or if he is late taking the daytime levodopa. The end-of-dose state consists of akinesia with severe burning in the right thigh and shoulder, all of which resolve after the next dose of LD takes effect. This patient also complained of profuse sweating as an end-of-dose phenomenon but this symptom occurs mostly during the night when his LD is spaced at intervals greater than 2.5 hours.

Patient 3 (sensory dyspnea).

A 73-year-old woman with PD for 15 years developed motor fluctuations 10 years ago. She takes immediate-release CD/LD (10/100 mg) at 4 AM, 6 AM, and 8 PM combined with controlled-release CD/LD (50/200 mg) at 8 AM, 12 noon, 4 PM, and 12 midnight. She also takes bromocriptine (10 mg) at 8 AM, 12 noon, and 4 PM. Her "off" periods generally conform to an end-of-dose wearing-off pattern but also occur unpredictably. They consist of moderate akinesia frequently accompanied by a sensation that she will not be able to take another breath. The patient states that this feeling is not associated with a sense of anxiety. Observers (including one of us, J.I.S.) during such periods do not see any abnormalities in breathing. This sensation disappears within minutes after she feels the next LD dose taking effect. She also suffers from swelling of the right foot, which begins within 15 minutes after the onset of most "off" periods and lasts until 30 minutes after the onset of the next "on."

Patient 4 (cough).

A 73-year-old woman with PD for 9 years started taking CD/LD 2 years ago. She developed motor fluctuations a year after starting treatment requiring CD/LD (25/100 mg) every 2 hours from 10 AM to 8 PM. End-of-dose failure consisted of bradykinesia accompanied by severe coughing, which lasted until the next dose of medication began to take effect. Switching to controlled-release CD/LD (50/200 mg) every 3 hours after the first morning dose of immediate-release medication eliminated the daytime "off" periods. After her last dose in the evening, she still has the same symptoms, which continue for several hours until she falls asleep. In the morning she is mobile without cough prior to her first dose of LD. She had developed hallucinations on further increases in daily LD or with the addition of bromocriptine.

Patient 5 (trigeminal neuralgia).

A 69-year-old woman with PD for 35 years developed motor fluctuations 14 years ago. The patient took immediate-release CD/LD (10/100 mg) every 2 hours from 2 AM to 10 PM and pergolide 0.5 mg at 6 AM, 5 PM, and 10 PM. She has complained of intermittent right-sided facial pains for 11 years. The pain shoots from the corner of her mouth up to the lateral part of the eye, is knifelike in character, and lasts seconds. Stimuli, such as touching the face, do not alter the onset of the pain. MRI of the brain was normal and carbamazepine was of no benefit. The patient noted that the pain only appeared during "off" periods accompanying the onset of tremor and bradykinesia, and disappeared as soon as the next dose of LD became effective. Increasing the pergolide to an every-6-hours schedule eliminated the pain.

Patient 6 (hand swelling).

A 76-year-old man with PD for 9 years and LD treatment for 6 years noted the onset of motor fluctuations 4 years ago. End-of-dose failure consists of akinesia and hypophonia. He noted wearing off at 4 hours on a schedule of immediate-release CD/LD (25/100 mg) at 8 AM, 12 noon, and 6 PM. During the past year, the patient has experienced right hand swelling, which begins about 15 minutes after onset of the "off" period and persists until approximately 30 minutes after the next dose becomes effective. One of the authors (J.I.S.) witnessed an episode of hand swelling during an office visit. During this episode, the right hand had less movement than the left, but was by no means immobile. Increasing the frequency of standard CD/LD to 8 AM, 12 noon, 4 PM, and 8 PM relieved the right hand swelling.

Patient 7 (hunger).

This 73-year-old woman with PD for 4 years recently started having end-of-dose failure 30 minutes before her next dose. She is taking controlled-release CD/LD, 50/200 mg at 8 AM, 25/100 mg at 12:30 PM, and 50/200 mg at 9 PM. Just before a mild end-of-dose tremor appears, the patient is overwhelmed by extreme hunger, which resolves as soon as the next dose becomes effective. The hunger appears and disappears whether she has eaten or not.

Patient 8 (abdominal distension).

This 73-year-old woman with PD for 12 years has had end-of-dose failure for the past 7 years. She took controlled-release CD/LD (50/200 mg) at 8 AM, 1 PM, and 6 PM. This schedule produced an "off" state 30 minutes prior to the next dose, which lasted for up to 2 hours. "Off" periods consisted of bradykinesia and fatigue. She complained of abdominal bloating and severe abdominal pain with her "off" periods, a problem that was so bad at night that it kept her from sleeping. Adding a dose of CD/LD (25/100 mg) at 11 PM made the nighttime pain and bloating disappear completely.

Discussion.

The categorization of nonmotor fluctuations into three major subgroups (autonomic, cognitive/psychiatric, and sensory) [6] was generally useful in classifying our patients. Autonomic complaints were the most common (44%), followed by cognitive/psychiatric (32%), and sensory symptoms (24%). The one major difficulty was where to place sensory dyspnea. A number of these episodes in several patients were witnessed by one of us (J.I.S.). These patients were in distress in the sense that they told the examiner that it "felt as if they could not take another breath." The breathing patterns and rates, however, were normal throughout each episode, suggesting that this complaint was not caused by rigidity of the respiratory musculature. Spouses corroborated that this was also the case for episodes that occurred at home. Despite the discomfort, patients stated that they were not anxious. There was no evidence of autonomic or motor dysfunction during each episode other than the usual "off" phenomena characteristic of that patient. In particular, there was no stridor [7] or other evidence of upper-airway obstruction, and there was no dystonia or chorea. [8] It appeared, therefore, to be a sensation of dyspnea rather than actual respiratory difficulty and, for this reason, we elected to classify these symptoms as sensory in nature.

Another unusual sensory phenomenon was pain in the proximal arm and pectoral area. This particular distribution of "off"-period pain, noted previously by Quinn et al., [9] is not common. Most pains and paresthesias mimic radicular or neuropathic patterns, suggesting a spinal cord, peripheral nerve, or autonomic nervous system origin to "off"-period pain. [9-13] The proximal limb location in one of the patients, and the symptoms mimicking trigeminal neuralgia, may suggest an origin for these pains above the level of the spinal cord in the basal ganglia or substantia nigra. [14-18] A number of sensory stimuli produce electrophysiologic responses in the basal ganglia cells. [19] This striatal activity is thought to be mainly inhibitory to sensory pathways. Sensory phenomena during hypodopaminergic states may thus be interpreted as direct effect from release from basal ganglia inhibition. Other nuclei, such as the locus ceruleus, are also inhibitory and have connections that include projection areas such as the spinal trigeminal nucleus. [20] Hypodopaminergic states, therefore, also may produce proximal limb or trigeminal neuralgia-like pain indirectly by influencing nondopaminergic nuclei and pathways. [21]

Symptoms of autonomic dysfunction [22,23] are the most common nonmotor "off" phenomena. Previously reported findings include anal sphincter contraction, abdominal bloating, belching, blood-pressure changes, urinary frequency, pupillary dilation, tachycardia, pallor, temperature changes, and profuse sweating. [6,24-26] New "off" phenomena that we describe in this paper include nausea, cough, hunger, limb edema, and facial flushing. Abdominal bloating and belching probably have the same underlying mechanism, bowel hypomotility. Abdominal pain is probably related to gastrointestinal hypomotility with increased gas and bowel distension. Limb edema is commonly due to poor mobility in PD and is often present in the legs as an early sign, sometimes predating a firm diagnosis. Edema in our cases occurred rapidly, was present in the hand in one patient, and disappeared within an hour or less. Poor mobility of the limb during an "off" period is, therefore, an improbable explanation for this phenomenon. Lewy body pathology causing dysfunction in multiple sites of the autonomic nervous system with subsequent vasomotor instability is a more likely explanation.

Cognitive/psychiatric complaints made up a third of all "off" period nonmotor symptoms. Although episodic depression, anxiety, and moaning/screaming are serious complications of PD, [27,28] panic attacks are the most debilitating. Panic begins abruptly with many patients describing an uncontrolled feeling that death is imminent. This frightening sensation disappears just as suddenly with the onset of the next "on" state, or if the patient remains "off" by not taking another dose of LD for several hours. Previous reports have suggested that panic attacks in PD patients usually occur in the setting of more generalized anxiety. [27,28] This is not always true since some of our patients with panic attacks were only anxious during a low-dopa state (end-of-dose wearing off). Although we listed anxiety and panic in separate categories of nonmotor fluctuations, this distinction is perhaps arbitrary. More likely, there is a continuum from mild "off" period anxiety to severe panic. Depression is present in at least half the patients who had panic attacks or anxiety. The high frequency of cognitive/psychiatric dysfunction may indicate that these patients are beginning to have Lewy body pathology outside the confines of the substantia nigra and other usual brainstem nuclei (diffuse Lewy body disease). [29]

Treatment of nonmotor "off" phenomena is not always possible but should be aimed at diminishing the amount of "off" time. Adding a dopamine agonist, using controlled-release preparations of LD, or increasing the frequency of dopaminergic medication may be helpful to some of these patients. Recognition of these symptoms as "off" phenomena will prevent unnecessary diagnostic tests and useless treatments.

  • Copyright 1996 by Advanstar Communications Inc.

REFERENCES

  1. 1.↵
    Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1988;24:363-365.
    OpenUrlPubMed
  2. 2.↵
    Sage JI, Mark MH. Basic mechanisms of motor fluctuations. Neurology 1994;44(Suppl 6):S10-S14.
  3. 3.↵
    Sage JI, Mark MH, McHale DM, Sonsalla PK, Vitagliano D. Benefits of monitoring plasma levodopa in Parkinson's disease patients with drug-induced chorea. Ann Neurol 1991;29:623-628.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
    OpenUrl
  5. 5.↵
    McHale DM, Sage JI, Sonsalla PK, Vitagliano D. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile. Clin Neuropharmacol 1990;13:164-170.
    OpenUrlPubMed
  6. 6.↵
    Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Vincken WG, Daraway CM, Cosio MG. Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease. Chest 1989;96:210-212.
    OpenUrlPubMed
  8. 8.↵
    Ilson J, Braun N, Fahn S. Respiratory fluctuations in Parkinson's disease [abstract]. Neurology 1983;33(suppl 2):113.
  9. 9.↵
    Quinn NP, Lang AE, Koller WC, Marsden CD. Painful Parkinson's disease. Lancet 1986;1:1366-1369.
    OpenUrlPubMed
  10. 10.
    Koller WC. Sensory symptoms in Parkinson's disease. Neurology 1984;34:957-959.
    OpenUrl
  11. 11.
    Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology 1976;26:423-429.
    OpenUrl
  12. 12.
    Sage JI, Kortis HI, Sommer W. Evidence for the role of spinal cord systems in Parkinson's disease-associated pain. Clin Neuropharmacol 1990;13:171-174.
    OpenUrlPubMed
  13. 13.
    Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DG. Pain in idiopathic Parkinson's disease [abstract]. Neurology 1985;35:200.
    OpenUrl
  14. 14.↵
    Nutt G, Carter JH. Sensory symptoms in parkinsonism related to central dopaminergic function. Lancet 1984;2:456-457.
    OpenUrlPubMed
  15. 15.
    Bendrups A, McKenzie J. Suppression of ectralemniscal thalamic unit responses by substantia nigra stimulation. Brain Res 1974;80:131-134.
    OpenUrlCrossRefPubMed
  16. 16.
    Rosner B, Davis R. Somatosensory activity in the human caudate nucleus. In: Kenshalo D, ed. The skin senses. Springfield: Charles C. Thomas, 1968:575-586.
  17. 17.
    Marsden CD. The mysterious motor function of the basal ganglia. The Robert Wartenberg Lecture. Neurology 1982;32:514-539.
    OpenUrl
  18. 18.
    Nauta HJW. A proposed conceptual reorganization of the basal ganglia and telencephalon. Neuroscience 1979;4:1875-1881.
    OpenUrlCrossRefPubMed
  19. 19.↵
    Krauthamer G, Felty P, Albe-Fessard D. Neurons of the medial diencephalon. II. Excitation of central origin. J Neurophysiol 1967;30:81-97.
    OpenUrl
  20. 20.↵
    Sasa N, Munekiyo K, Ikeda H, et al. Noradrenaline-mediated inhibition by locus ceruleus of spinal trigeminal neurons. Brain Res 1974;80:443-460.
    OpenUrl
  21. 21.↵
    Anden NE, Dahlstrom A, Fuxe K, et al. Ascending monoamine neurones to the telencephalon and diencephalon. Acta Physiol Soand 1966;67:313-326.
    OpenUrl
  22. 22.↵
    Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson's disease. Neurology 1986;36:73-75.
    OpenUrlAbstract/FREE Full Text
  23. 23.
    Tanner CM, Goetz CG, Klawans HL. Autonomic nervous system disorders in Parkinson's disease. In: Koller WC, ed. Handbook of Parkinson's disease. NY: Marcel Dekker, 1992;185-215.
  24. 24.
    Fitzmaurice H, Fowler CJ, Rickards D, et al. Micturition disturbance in Parkinson's disease. Br J Urol 1985;57:652-656.
    OpenUrlPubMed
  25. 25.
    Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to levodopa profile. Ann Neurol 1995;37:120-122.
    OpenUrlPubMed
  26. 26.
    Pfeiffer RF, Sucha EL. "On-off"-induced lethal hyperthermia. Mov Disord 1989;4:338-341.
    OpenUrl
  27. 27.↵
    Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990;147:217-220.
    OpenUrl
  28. 28.
    Routh LC, Black JL, Ahlskog JE. Parkinson's disease complicated by anxiety. Mayo Clin Proc 1987;62:733-735.
    OpenUrl
  29. 29.↵
    Sage JI, Mark MH. Diffuse Lewy body disease. In: Stern MB, Koller WC, eds. Parkinsonian syndromes. New York: Marcel Dekker, 1993;393-411.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Patients and results.
    • Discussion.
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise